| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Shanghai Haohai Biological Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$65.91 |
| 52 Week High | HK$89.27 |
| 52 Week Low | HK$55.54 |
| Beta | 0.74 |
| 11 Month Change | -11.41% |
| 3 Month Change | 8.23% |
| 1 Year Change | -10.30% |
| 33 Year Change | -31.57% |
| 5 Year Change | 9.90% |
| Change since IPO | -29.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688366 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -5.2% | -4.1% | -1.2% |
| 1Y | -10.3% | -16.9% | 3.1% |
Return vs Industry: 688366 exceeded the CN Biotechs industry which returned -16.9% over the past year.
Return vs Market: 688366 underperformed the CN Market which returned 3.1% over the past year.
Price Volatility
| 688366 volatility | |
|---|---|
| 688366 Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in CN Market | 12.0% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 688366 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688366's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 2,179 | Jianying Wu | www.3healthcare.com |
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. The company offers ophthalmology products consisting intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop.
Shanghai Haohai Biological Technology Co., Ltd. Fundamentals Summary
| 688366 fundamental statistics | |
|---|---|
| Market cap | CN¥13.67b |
| Earnings (TTM) | CN¥430.21m |
| Revenue (TTM) | CN¥2.75b |
15.0x
P/E Ratio2.3x
P/S RatioIs 688366 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688366 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.75b |
| Cost of Revenue | CN¥848.86m |
| Gross Profit | CN¥1.90b |
| Other Expenses | CN¥1.47b |
| Earnings | CN¥430.21m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.86 |
| Gross Margin | 69.10% |
| Net Profit Margin | 15.66% |
| Debt/Equity Ratio | 7.0% |
How did 688366 perform over the long term?
See historical performance and comparison